Clearside Biomedical, Inc. (CLSDQ)

SEC fundamentals · as filed in 10-Q FY2025, period ended Sep 30, 2025 · updated Oct 6, 2026

Verified against EDGAR
Total Assets
$11.6M
Stockholders' Equity
-$54.0M
Cash & Equivalents
$6.8M
Long-Term Debt
—

as filed in 10-Q FY2025, period ended Sep 30, 2025 · View filings on EDGAR ↗

In its 10-Q for the period ended Sep 30, 2025, Clearside Biomedical, Inc. reported revenue of $201,000, net income of -$6.0M, and total assets of $11.6M. Every figure below is taken directly from Clearside Biomedical, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2016–FY2024 · as reported

$29.6M-$26.6M-$82.8M
FY2016FY2018FY2020FY2022FY2024
Revenue$1.7MNet income-$34.4M
FY2016 revenue
$520,000
FY2024 revenue
$1.7M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2024$1.7M-$34.4M
FY2023$8.2M-$32.5M
FY2022$1.3M-$32.9M
FY2021$29.6M$376,000
FY2020$7.9M-$18.2M
FY2019$2.2M-$30.8M
FY2018$30,000-$82.8M
FY2017$345,000-$59.0M
FY2016$520,000-$25.9M
FY2015—-$17.6M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KDec 29, 2025on EDGAR ↗
8-KDec 8, 2025on EDGAR ↗
8-KNov 25, 2025on EDGAR ↗
10-QNov 14, 2025on EDGAR ↗
8-KOct 7, 2025on EDGAR ↗
8-KSep 11, 2025on EDGAR ↗
8-KSep 11, 2025on EDGAR ↗
8-KSep 8, 2025on EDGAR ↗
8-KSep 3, 2025on EDGAR ↗
8-KAug 14, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Sep 30, 2025 · 10-Q

Total Assets$11.6Msource ↗
Stockholders’ Equity-$54.0Msource ↗
Cash & Equivalents$6.8Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Sep 30, 2025

Revenue$201,000source ↗
Net Income-$6.0Msource ↗
Operating Income-$7.0Msource ↗
Gross Profit$201,000source ↗
Cost of Revenue$0source ↗
R&D Expense$2.9Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Sep 30, 2025

EPS (diluted)$-1.14source ↗
EPS (basic)$-1.14source ↗
Shares Outstanding5.2Msource ↗
Cash from Operations-$5.5Msource ↗
Cash from Financing$2.9Msource ↗
Cash from Investing$0source ↗

Restatement history

Point-in-time

1 of 261 annual fact-keys were materially restated between filings: what Clearside Biomedical, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches CLSDQ’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CLSDQ

MCP tool: get_sec_fundamentals ticker=CLSDQ

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CLSDQ/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=CLSDQ as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CLSDQ/history

MCP tool: get_fundamentals_history ticker=CLSDQ

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/CLSDQ

MCP tool: get_financial_health ticker=CLSDQ

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.